HeartBeam Inc. (NASDAQ: BEAT) announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia—a condition of inadequate blood flow and oxygen supply to tissue. The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to fill a critical gap. According to the company, ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could provide physicians with a powerful tool for early detection and monitoring of coronary artery disease.”
The pilot study marks a milestone in HeartBeam's product development, with implications for the broader cardiac monitoring industry. If successful, the patch could offer a non-invasive, convenient way for patients to record clinical-quality ECGs on demand, potentially reducing the need for in-clinic visits and enabling earlier intervention. For the estimated 20.1 million adults with coronary artery disease in the U.S. alone, such technology could mean more proactive management of their condition.
HeartBeam's focus on on-demand 12-lead ECG sets it apart from existing continuous monitors, which typically use fewer leads and may miss transient ischemic events. The company's patch is designed to be worn for extended periods, allowing patients to capture ECGs when symptoms occur. This approach could improve diagnostic yield and reduce healthcare costs by avoiding unnecessary tests and hospitalizations.
The success of the pilot study could accelerate HeartBeam's path to market and challenge established players in the cardiac monitoring space. Investors and industry observers will be watching closely, as the outcomes may validate the technology's clinical utility and commercial viability. For more information on HeartBeam and its developments, visit the company's newsroom at https://nnw.fm/BEAT.
